Medical Necessity of Infliximab for Crohn's Disease

Introduction to Infliximab Treatment

The European Crohn's and Colitis Organisation (ECCO) strongly recommends infliximab as maintenance therapy for moderate-to-severe Crohn's disease with documented disease control (strong recommendation, low-quality evidence) 1
Infliximab is medically necessary for the treatment of Crohn's disease in patients with documented disease control, as recommended by the ECCO guidelines 2, 1

The ECCO guidelines recommend infliximab as maintenance therapy in moderate-to-severe Crohn's disease (strong recommendation, low-quality evidence) 1
Patients with Crohn's disease of both small and large intestine require ongoing management, as indicated by the patient's documented Crohn's disease (K50.80) 3
Clinical response to infliximab is indicated by documented improvement in signs and symptoms of the condition, such as the patient's disease being "well controlled" since increasing infliximab to 10mg/kg 3

Standard maintenance dosing of infliximab is 5 mg/kg IV every 8 weeks, according to the FDA-approved parameters 4, 3
Dose escalation to 10 mg/kg every 8 weeks is appropriate for patients who respond and then lose response, as seen in this patient's current regimen 3, 5

Tuberculosis screening is required within 12 months of therapy, and the patient has completed this screening with a negative QuantiFERON TB Gold Plus test on 2/10/2025 3
Hepatitis B screening is also necessary prior to continuing biologic therapy, and the patient's screening was negative 3
Management by a gastroenterologist meets the specialty prescriber requirement for Crohn's disease, as indicated by the patient's management by a gastroenterologist 2, 4

Documented clinical response is necessary for continuation of therapy, and the patient's notes indicate "disease is well controlled since increasing inflectra to 10mg/kg" 3
Objective evidence of disease is provided by colonoscopy findings from July 2023, which document intestinal strictures 3
The patient's clinical response meets continuation criteria, as there is documented improvement in signs and symptoms of the condition 5

Continuation of infliximab is medically necessary for patients who achieve or maintain remission or who demonstrate positive clinical response, as indicated by the patient's documented clinical response 5
Long-term maintenance therapy with infliximab is supported by strong evidence for reducing disease progression and maintaining remission, according to the ECCO guidelines 1, 3

The European Crohn's and Colitis Organisation (ECCO) strongly recommends infliximab as maintenance therapy for moderate-to-severe Crohn's disease when patients achieve or maintain positive clinical response (strong recommendation, low-quality evidence) 6

The British Society of Gastroenterology suggests dose optimization informed by therapeutic drug monitoring for secondary loss of response 7
The Canadian Association of Gastroenterology conditionally recommends dose intensification for suboptimal response, guided by therapeutic drug monitoring (conditional recommendation, very low-quality evidence) 8
Doubling the dose (10 mg/kg every 8 weeks) may be more convenient and cost-effective than interval shortening 7

No guideline or research study supports 16 mg/kg dosing for Crohn's disease 9, 10, 8, 11, 7, 12, 6

Measure infliximab trough levels and anti-drug antibodies to guide dose adjustment 8, 7
If low drug levels with negative antibodies: increase to 10 mg/kg every 8 weeks 7
If low drug levels with positive antibodies: consider adding immunomodulator (azathioprine or methotrexate) or switching therapy 7, 6

Ensure tuberculosis screening remains current, hepatitis B monitoring continues, complete blood count monitoring for cytopenias, assessment for infections before each infusion, and monitoring for hepatosplenic T-cell lymphoma risk if combining with immunomodulator 8, 7